Kovitz Investment Group Partners
VRCA icon

Kovitz Investment Group Partners’s Verrica Pharmaceuticals VRCA Stock Holding History

Kovitz Investment Group Partners’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,113
Closed -$44.7K – 1402
2025
Q1 		$44.7K Hold
10,113
– – ﹤0.01% 1231
2024
Q4 		$70.8K Hold
10,113
– – ﹤0.01% 1212
2024
Q3 		$147K Buy
10,113
+100
+1% +$4.5K ﹤0.01% 968
2024
Q2 		$730K Buy
10,013
+5,000
+100% +$384K 0.01% 604
2024
Q1 		$297K Hold
5,013
– – ﹤0.01% 585
2023
Q4 		$367K Hold
5,013
– – 0.01% 347
2023
Q3 		$195K Buy
5,013
+1,540
+44% +$78.3K ﹤0.01% 384
2023
Q2 		$200K Hold
3,473
– – ﹤0.01% 398
2023
Q1 		$226K Buy
3,473
+460
+15% +$27.8K ﹤0.01% 396
2022
Q4 		$83K Buy
+3,013
New +$80.4K ﹤0.01% 388

Other funds holding VRCA

CP
Caligan Partners New York $1.41B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return